Internal Medicine, Hematology · Columbus, OH
NPI
1053679217
Since 2012
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
460 W 10th Ave
Columbus, OH, 43210
Phone (614) 293-3196
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
335 services
Medicare patients, 2024
80
Average age 71
Drug cost, 2024
$3.2M
334 prescriptions
Company payments, 2025
$1,321
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gregory K Behbehani was code 99233 (hospital e&m - subsequent), 135 times for 33 patients. In total Gregory K Behbehani billed 335 services in 13 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 135 | 33 | $89.78 | $12K |
| 99214 Office E&M - Established | Facility | 101 | 32 | $70.80 | $7,151 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 31 | 18 | $12.44 | $386 |
| 99215 Office E&M - Established | Facility | 16 | 13 | $101.50 | $1,624 |
| 99205 Office E&M - New | Facility | 11 | 11 | $137.15 | $1,509 |
By year: 2022 $21K for 270 services; 2023 $20K for 253 services; 2024 $26K for 335 services.
Medicare prescription drug claims, 2024
In 2024, the drug Gregory K Behbehani prescribed most often to Medicare patients was Idhifa (Enasidenib Mesylate), with 32 prescriptions and refills. In total Gregory K Behbehani wrote 334 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Idhifa Enasidenib Mesylate | 32 | 32 | Under 11 | $1.1M |
| Venclexta Venetoclax | 25 | 25 | 11 | $39K |
| Tibsovo Ivosidenib | 21 | 21 | Under 11 | $670K |
| Xospata Gilteritinib Fumarate | 20 | 20 | Under 11 | $280K |
| Hydroxyurea Generic | 19 | 23 | Under 11 | $184 |
| Ondansetron Hcl Generic | 18 | 18 | Under 11 | $117 |
| Imatinib Mesylate Generic | 14 | 14 | Under 11 | $55K |
| Acyclovir Generic | 14 | 14 | Under 11 | $103 |
| Bosulif Bosutinib | 12 | 12 | Under 11 | $226K |
| Inqovi Decitabine/Cedazuridine | 11 | 11 | Under 11 | $93K |
Brand drugs: 150 claims; generic drugs: 184 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gregory K Behbehani $1,321 ($1,321 in general payments such as food, travel and fees) from 3 companies. The largest payer was Adaptive Biotechnologies Corporation with $1,197.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.